What's Happening?
Avner Schlessinger, PhD, has been named the new chair of the UNC Department of Pharmacology at the University of North Carolina at Chapel Hill. Dr. Schlessinger is slated to begin his tenure in February 2027. He will succeed Henrik Dohlman, PhD, who will step
down from the chair position in February but will remain a faculty member within the department. Dr. Schlessinger is currently the director of the AI Small Molecule Drug Discovery Center and the Dr. Amy and James Elster Professor of Molecular Biology and a professor of pharmacological sciences at the Icahn School of Medicine at Mount Sinai. His research focuses on integrating computational chemistry, artificial intelligence, structural biology, and experimental pharmacology to improve and automate the structure-based drug discovery process. He holds a B.Sc. in chemistry and biology from Tel Aviv University and a PhD in biochemistry and molecular biophysics from Columbia University.
Why It's Important?
The appointment of Dr. Schlessinger is significant for the UNC School of Medicine and the broader field of drug discovery. His expertise in AI-enabled drug discovery, computational and structural pharmacology, and chemical biology is expected to be a substantial asset. Samantha Meltzer-Brody, MD, MPH, executive dean of the UNC School of Medicine and chief academic officer of UNC Health, highlighted Dr. Schlessinger's world-renowned research and his ability to integrate cutting-edge approaches. This leadership change signals a strategic move towards enhancing the department's capabilities in advanced drug discovery methods, particularly those leveraging artificial intelligence. This could lead to accelerated development of new small-molecule therapeutics and a deeper understanding of disease mechanisms, precision medicine, and pharmacogenomics, ultimately benefiting patient care and medical innovation in the U.S.
What's Next?
Dr. Schlessinger will officially assume his role as chair in February 2027. In the interim, the department will likely prepare for this leadership transition, with Dr. Dohlman continuing in his current capacity until then. Upon his arrival, Dr. Schlessinger is expected to implement his vision for advancing the department's research and educational missions, particularly in the areas of AI-driven drug discovery. This transition could involve new research initiatives, collaborations, and potentially the recruitment of additional talent aligned with his expertise. The UNC School of Medicine anticipates that his leadership will foster innovation and scientific excellence, contributing to the institution's tripartite mission of patient care, education, and research.
Beyond the Headlines
Dr. Schlessinger's appointment underscores a growing trend in medical research: the increasing reliance on artificial intelligence and computational methods to revolutionize drug discovery. His background suggests a future where the traditional, often lengthy, and costly process of drug development could become more efficient and targeted. This shift has profound implications for the pharmaceutical industry, potentially leading to faster identification of therapeutic compounds and more personalized treatment approaches. The integration of AI in pharmacology also raises questions about data privacy, the ethical use of AI in medical research, and the need for a highly skilled workforce capable of navigating these advanced technologies. UNC's investment in this area positions it at the forefront of a transformative era in medicine, potentially influencing national research priorities and funding allocations in the coming years.
